Original Report

Treatment outcomes in stage IIIA non–small-cell lung cancer in a community cancer center


 

Background Treatment outcomes for non-small-cell lung cancer (NSCLC) patients diagnosed at stage IIIA have been analyzed in many studies, which generally involve patients younger and healthier than the average patient with this disease.

Objective To analyze demographics and treatment outcomes in patients with stage IIIA NSCLC at a community cancer center.

Methods We reviewed charts of 226 patients diagnosed with stage IIIA NSCLC from January 2003 to December 2008 treated at our community cancer center. Results Median overall survival for all patients and sequentially and concurrently treated chemoradiation patients were 18 months, and 18 months, and 20 months, respectively. Median overall survival for women and men was 24 months and 16 months, respectively.

Limitations Study design was retrospective and some medical records were not available. However, this population is likely representative of patients treated in similar settings.

Conclusions In our population, advanced age and male gender were associated with lower median survival. Responses to concurrent and sequential chemoradiation seemed to differ based on age group, which may be useful as a prognostic guideline for similar populations.

Funding Helen F Graham Cancer Center and Research Institute

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Gefitinib approved for first-line EGFR-positive metastatic NSCLC
MDedge Hematology and Oncology
ASCO 2015: from data and learning, to daily practice
MDedge Hematology and Oncology
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
MDedge Hematology and Oncology
Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Lung cancer biomarker moves into the clinic
MDedge Hematology and Oncology
Limited resection inferior for elderly with early NSCLC
MDedge Hematology and Oncology
Solid histology predicts poor survival in resected lung adenocarcinoma
MDedge Hematology and Oncology
Immune-related patterns of response present challenges
MDedge Hematology and Oncology
Vemurafenib looks promising for several nonmelanoma malignancies
MDedge Hematology and Oncology
Lung cancer in HIV-infected patients and the role of targeted therapy
MDedge Hematology and Oncology